- Investing Ideas
- Global Pharmaceuticals & Biotech Top Growth Stocks
Global Pharmaceuticals & Biotech Top Growth Stocks
Results
72
72 companies
Beijing Luzhu Biotechnology
Market Cap: HK$2.6b
A biotechnology company, develops human vaccines and therapeutic biologics to prevent and control infectious diseases, and to treat cancer and autoimmune diseases in Mainland China.
2480
HK$12.90
7D
1.3%
1Y
-42.7%
Axsome Therapeutics
Market Cap: US$12.2b
A biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States.
AXSM
US$237.04
7D
-4.8%
1Y
111.2%
Madrigal Pharmaceuticals
Market Cap: US$12.7b
A biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States.
MDGL
US$545.53
7D
-2.6%
1Y
56.4%
Starpharma Holdings
Market Cap: AU$307.4m
A biopharmaceutical company, engages in the research, development and commercialization of dendrimer technology for pharmaceutical, healthcare applications, life science, and other applications in Australia and internationally.
SPL
AU$0.73
7D
0%
1Y
630.0%
Oscotec
Market Cap: ₩1.2t
Operates as a biotechnology company, engages in the drug development, functional materials and related products, and dental bone graft material businesses.
A039200
₩30,150.00
7D
-3.4%
1Y
-13.0%
Syndax Pharmaceuticals
Market Cap: US$2.1b
A commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer.
SNDX
US$22.71
7D
-8.6%
1Y
134.9%
Camurus
Market Cap: SEK 38.0b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMX
SEK 639.00
7D
16.2%
1Y
-7.9%
HansBiomed
Market Cap: ₩326.6b
Engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies.
A042520
₩22,900.00
7D
-4.2%
1Y
159.6%
Neuren Pharmaceuticals
Market Cap: AU$2.2b
A biopharmaceutical company, develops drugs for the treatment of neurological disorders.
NEU
AU$17.51
7D
4.4%
1Y
18.0%
Kuros Biosciences
Market Cap: CHF 820.0m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURN
CHF 20.78
7D
-2.8%
1Y
-28.4%
Bonesupport Holding
Market Cap: SEK 13.6b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEX
SEK 206.60
7D
-13.9%
1Y
-36.2%
MedinCell
Market Cap: €915.6m
A clinical-stage and commercial biopharmaceutical licensing company, develops long acting injectables in various therapeutic areas in France.
MEDCL
€25.50
7D
-8.4%
1Y
59.3%
Akeso
Market Cap: HK$93.8b
A biopharmaceutical company, engages in the research, development, manufacture, and commercialization of antibody drugs worldwide.
9926
HK$101.80
7D
7.6%
1Y
-27.0%
AnaptysBio
Market Cap: US$1.7b
A clinical-stage biotechnology company, focuses in delivering immunology therapeutics for autoimmune and inflammatory diseases in the United States.
ANAB
US$54.15
7D
-18.7%
1Y
103.0%
Ardelyx
Market Cap: US$1.3b
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
ARDX
US$5.13
7D
-4.7%
1Y
13.4%
Cutia Therapeutics
Market Cap: HK$933.9m
An investment holding company, engages in the research, development, manufacture, and commercialization of scalp diseases and care products, and skin care products in the People’s Republic of China and Hong Kong.
2487
HK$2.57
7D
-4.5%
1Y
-74.9%
WuXi XDC Cayman
Market Cap: HK$75.0b
An investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.
2268
HK$59.30
7D
-0.2%
1Y
18.0%
Ocumension Therapeutics
Market Cap: HK$5.1b
Engages in the research, discovery, development, and commercialization of ophthalmic therapies in China.
1477
HK$6.22
7D
30.4%
1Y
-37.1%
Alnylam Pharmaceuticals
Market Cap: US$37.3b
Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally.
ALNY
US$283.15
7D
-9.5%
1Y
-12.8%
Capricor Therapeutics
Market Cap: US$1.2b
A clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States.
CAPR
US$19.12
7D
-15.0%
1Y
167.0%
Pharma Mar
Market Cap: €1.3b
A biopharmaceutical company, focuses on the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Germany, Ireland, France, Switzerland, rest of the European Union, the United States, and internationally.
PHM
€76.00
7D
-7.5%
1Y
-7.3%
Aldeyra Therapeutics
Market Cap: US$115.8m
A biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases.
ALDX
US$1.72
7D
-25.2%
1Y
-65.8%
DBV Technologies
Market Cap: €829.7m
A clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France.
DBV
€2.80
7D
-1.6%
1Y
67.1%
Intellia Therapeutics
Market Cap: US$1.8b
Operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies.
NTLA
US$11.86
7D
-23.2%
1Y
0.3%
Forum Markets
Market Cap: US$79.0m
A financial technology company, develops a blockchain-based platform focused on the acquisition, structuring, and tokenization of real-world assets worldwide.
FRMM
US$5.85
7D
-0.9%
1Y
-68.1%
Zevra Therapeutics
Market Cap: US$766.1m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$12.76
7D
-8.5%
1Y
0.8%
Bora Pharmaceuticals
Market Cap: NT$52.9b
Engages in contract development, manufacture, and sale of pharmaceuticals in Europe, the United States, Taiwan, and internationally.
6472
NT$415.50
7D
-2.5%
1Y
-39.9%
CG Oncology
Market Cap: US$6.4b
A late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States.
CGON
US$69.50
7D
-5.2%
1Y
144.2%
Arcutis Biotherapeutics
Market Cap: US$3.5b
A biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases.
ARQT
US$27.74
7D
-3.6%
1Y
79.2%
MindMaze Therapeutics Holding
Market Cap: CHF 24.3m
Operates as a commercial-stage biopharmaceutical and neurotechnology company in Asia, the United States, Switzerland, rest of Europe, and internationally.
MMTX
CHF 0.16
7D
-11.4%
1Y
n/a
Oxford Biomedica
Market Cap: UK£784.8m
A contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
OXB
UK£6.49
7D
6.4%
1Y
79.0%
Codexis
Market Cap: US$200.9m
Provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe, the Middle East, Africa, Australia, New Zealand, Southeast Asia, and China.
CDXS
US$2.16
7D
-15.6%
1Y
-25.0%
Genovis AB (publ.)
Market Cap: SEK 1.2b
Develops and sells tools for the development of new treatment methods and diagnostics in North America, Europe, and Asia.
GENO
SEK 18.92
7D
-0.4%
1Y
-31.8%
Insmed
Market Cap: US$23.8b
Develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
INSM
US$107.46
7D
-9.1%
1Y
3.2%
Vera Therapeutics
Market Cap: US$3.1b
A clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases.
VERA
US$39.12
7D
-7.8%
1Y
64.6%
SIGA Technologies
Market Cap: US$255.3m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$3.56
7D
1.7%
1Y
-46.9%